GlassScriptPhysician profile
Amber S Long
NPI 1902858095
$4,347.68
in general payments reported to CMS, 2019-2025
24 companies · $976 in 2025
The $976 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $555 · 2023: $1,416 · 2024: $1,065 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.56 |
| Education | $557.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.40 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $480.87 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $447.72 | 2021-2025 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $422.03 | 2021-2025 | Tremfya |
| Ucb, INC. | $241.32 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $240.64 | 2021-2024 | |
| Galderma Laboratories, L.P. | $226.72 | 2021-2024 | Aklief, Dysport, Oracea |
| E.R. Squibb & Sons, L.L.C. | $174.95 | 2022-2024 | Sotyktu |
| Incyte Corporation | $171.92 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $154.92 | 2024-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $125.44 | 2023-2025 | Zoryve |
| Amgen INC. | $92.92 | 2021-2024 | Otezla |
| Dermavant Sciences, INC. | $91.16 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.34 | 2023-2025 | Cabtreo, Jublia |
| Pfizer INC. | $76.41 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.62 | 2024-2025 | Dupixent |
| Biofrontera INC. | $48.15 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Almirall LLC | $40.30 | 2021-2022 | |
| Organon LLC | $39.38 | 2025 | Vtama |
| Biocon Biologics INC | $29.12 | 2023 | Hulio |
| Journey Medical Corporation | $26.29 | 2021-2022 | |
| Mylan Institutional INC. | $23.00 | 2023 | Hulio |
| Lilly USA, LLC | $20.90 | 2023 | Taltz, Olumiant |
| Organogenesis INC. | $19.16 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.